LEO Pharma is a foundation-owned, fully-integrated pharmaceutical company dating more than 100 years back.
At LEO Pharma Research & Development (R&D) in Denmark, we discover and develop novel therapies within the LEO focus areas dermatology and critical care, and as one of the world’s leading companies within dermatology, it is our ambition to function as a center of expertise for the treatment of psoriasis, eczema and actinic keratosis.
We devote our entire R&D efforts to develop innovative and competitive drugs within these two therapeutic focus areas. Our current R&D projects focus on:
- Actinic keratosis
- Inflammatory indications
- Non-melanoma skin cancer
To ensure sufficient funding for our R&D activities, 14% of the LEO Pharma revenue is allocated to research and development of new drugs.
For more information about LEO Pharma R&D visit our global site at www.leo-pharma.com.